ArticleMolecular pharmaceutics
Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited.
Article in Molecular pharmaceutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 230 citations in OpenAlex.
- Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections.Pharmaceutical research · 2022Pooled it
- Minimally Invasive Endovascular Administration for Targeted PLGA Nanoparticles Delivery to Brain, Salivary Glands, Kidney and Lower Limbs.Pharmaceutics · 2026Article
- Ceria-nanocluster based therapy for Alzheimer's disease through the modulation of activated microglia and attenuation of amyloid-β deposition.Cell biomaterials · 2025Article
- Surface Functionalized Polyhydroxyalkanoate Nanoparticles via SpyTag-SpyCatcher System for Targeted Breast Cancer Treatment.Pharmaceutics · 2025Article
- MF59-based lipid nanocarriers for paclitaxel delivery: optimization and anticancer evaluation.Scientific reports · 2025Article
- Synergistic nano-vaccine strategy for comprehensive activation of adaptive and innate immunity againstFrontiers in immunology · 2025Article
- Vaccination-Route-Dependent Adjuvanticity of Antigen-Carrying Nanoparticles for Enhanced Vaccine Efficacy.Vaccines · 2024Article
- Article
- Article
- Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.International journal of molecular sciences · 2022Article
- Robust Chemical Strategy for Stably Labeling Polyester-Based Nanoparticles with BODIPY Fluorophores.ACS applied polymer materials · 2022Article
- Article
- Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.Advances in experimental medicine and biology · 2021Review
- Coherent Raman Scattering Microscopy in Oncology Pharmacokinetic Research.Frontiers in pharmacology · 2021Review
- Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines.Scientific reports · 2020Article
- Biocompatibility of Biomaterials for Nanoencapsulation: Current Approaches.Nanomaterials (Basel, Switzerland) · 2020Review
- Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Spatially Resolved Correlation between Stiffness Increase and Actin Aggregation around Nanofibers Internalized in Living Macrophages.Materials (Basel, Switzerland) · 2020Article
- Intravenously Administered, Retinoid Activating Nanoparticles Increase Lifespan and Reduce Neurodegeneration in the SOD1Frontiers in bioengineering and biotechnology · 2020Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
We reexamined the cellular drug delivery mechanism by poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) to determine their utility and limitations as an intracellular drug delivery system. First, we prepared PLGA NPs which physically encapsulated Nile red (a hydrophobic fluorescent dye), in accordance with the usual procedure for labeling PLGA NPs, incubated them with mesothelial cells, and observed an increase in the intracellular fluorescence. We then prepared NPs from PLGA chemically conjugated to a fluorescent dye and observed their uptake by the mesothelial cells using confocal microscopy. We also used coherent anti-Stokes Raman scattering (CARS) microscopy to image cellular uptake of unlabeled PLGA NPs. Results of this study coherently suggest that PLGA NPs (i) are not readily taken up by cells, but (ii) deliver the payload to cells by extracellular drug release and/or direct drug transfer to contacting cells, which are contrasted with the prevalent view. From this alternative standpoint, we analyzed cytotoxicities of doxorubicin and paclitaxel delivered by PLGA NPs and compared with those of free drugs. Finally, we revisit previous findings in the literature and discuss potential strategies to achieve efficient drug delivery to the target tissues using PLGA NPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.